Introduction: Antiretroviral-based pre-exposure prophylaxis (PrEP) is today an established,
effective and safe method of HIV prevention used in multiple countries worldwide by a broad
range of populations at risk of HIV infection. Biomedical innovations are critical in supporting
the primary prevention of HIV; however, their potential can only be maximized if end-user
challenges are recognized, described and used to develop next-generation models.
Discussion: First-generation PrEP, a daily oral pill, is highly efficacious, discreet and affords …